MCI1
MCID: MYC007
MIFTS: 70

Myocardial Infarction (MCI1)

Categories: Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Myocardial Infarction

MalaCards integrated aliases for Myocardial Infarction:

Name: Myocardial Infarction 56 12 36 29 54 6 43 15 37 17 71
Heart Attack 12 74 42 15 62
Myocardial Infarction 1 73 29 6
Myocardial Infarction, Decreased Susceptibility to 56 6
Myocardial Infarction, Protection Against 56 6
Myocardial Infarction, Susceptibility to, Type 1 39
Myocardial Infarction, Susceptibility to 56
Myocardial Infarction, Decreased 56
Premature Myocardial Infarction 73
Myocardial Infarct 12
Mci1 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5844
OMIM 56 608446
KEGG 36 H01730
MeSH 43 D009203
NCIt 49 C27996
SNOMED-CT 67 22298006
ICD10 32 I21
UMLS 71 C0027051

Summaries for Myocardial Infarction

MedlinePlus : 42 Each year almost 800,000 Americans have a heart attack. A heart attack happens when blood flow to the heart suddenly becomes blocked. Without the blood coming in, the heart can't get oxygen. If not treated quickly, the heart muscle begins to die. But if you do get quick treatment, you may be able to prevent or limit damage to the heart muscle. That's why it's important to know the symptoms of a heart attack and call 911 if you or someone else is having them. You should call, even if you are not sure that it is a heart attack. The most common symptoms in men and women are Chest discomfort. It is often in center or left side of the chest. It usually lasts more than a few minutes. It may go away and come back. It can feel like pressure, squeezing, fullness, or pain. It also can feel like heartburn or indigestion. Shortness of breath. Sometimes this is your only symptom. You may get it before or during the chest discomfort. It can happen when you are resting or doing a little bit of physical activity. Discomfort in the upper body. You may feel pain or discomfort in one or both arms, the back, shoulders, neck, jaw, or upper part of the stomach. You may also have other symptoms, such as nausea, vomiting, dizziness, and lightheadedness. You may break out in a cold sweat. Sometimes women will have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks is coronary artery disease (CAD). With CAD, there is a buildup of cholesterol and other material, called plaque, on their inner walls or the arteries. This is atherosclerosis. It can build up for years. Eventually an area of plaque can rupture (break open). A blood clot can form around the plaque and block the artery. A less common cause of heart attack is a severe spasm (tightening) of a coronary artery. The spasm cuts off blood flow through the artery. At the hospital, health care providers make a diagnosis based on your symptoms, blood tests, and different heart health tests. Treatments may include medicines and medical procedures such as coronary angioplasty. After a heart attack, cardiac rehabilitation and lifestyle changes can help you recover. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Myocardial Infarction, also known as heart attack, is related to acute myocardial infarction and cardiovascular system disease, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Myocardial Infarction is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling and Transcriptional activation by NRF2. The drugs Trimetazidine and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include Bone and Limb.

Disease Ontology : 12 A coronary artery disease characterized by myocardial cell death (myocardial necrosis) due to prolonged ischaemia.

KEGG : 36 Myocardial infarction (MI) or acute myocardial infarction (AMI) is a term for an event of heart attack. It is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply. The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, nausea, epigastric discomfort, syncope, diaphoresis, and other factors. The diagnosis of MI is dependent on the sensitivity and specificity of the clinical criteria, electrocardiographic (ECG) findings, imaging studies and biomarkers used to detect death of cardiomyocytes. The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack. Nitroglycerin and antihypertensive drugs such as beta-blockers and ACE inhibitors may also be used to lower blood pressure and to improve the oxygen demand of heart.

UniProtKB/Swiss-Prot : 73 Myocardial infarction 1: A condition defined by the irreversible necrosis of heart muscle secondary to prolonged ischemia.

PubMed Health : 62 About heart attack: A heart attack happens when the flow of oxygen-rich blood to a section of heart muscle suddenly becomes blocked and the heart can't get oxygen. If blood flow isn't restored quickly, the section of heart muscle begins to die. Heart attacks are a leading killer of both men and women in the United States. The good news is that excellent treatments are available for heart attacks. These treatments can save lives and prevent disabilities. Heart attack treatment works best when it's given right after symptoms occur. If you think you or someone else is having a heart attack (even if you're not fully sure), call 9–1–1 right away.

Wikipedia : 74 A myocardial infarction (MI), also known as a heart attack, occurs when blood flow decreases or stops to... more...

More information from OMIM: 608446

Related Diseases for Myocardial Infarction

Diseases in the Myocardial Infarction family:

Myocardial Infarction 2 Posterior Myocardial Infarction
Acute Myocardial Infarction

Diseases related to Myocardial Infarction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1356)
# Related Disease Score Top Affiliating Genes
1 acute myocardial infarction 35.9 OLR1 MIR499A MIR21 F7 CDKN2B-AS1
2 cardiovascular system disease 33.9 OLR1 MIR499A MIR210 MIR21 F7 ESR1
3 coronary heart disease 1 33.8 OLR1 F7 CDKN2B-AS1
4 cerebrovascular disease 32.5 MIR21 LTA ITGB3 F7 F13A1
5 stroke, ischemic 32.4 OLR1 MIAT F7 CDKN2B-AS1
6 thrombophilia 31.8 ITGB3 F7 F13A1
7 polymyositis 31.0 MIR210 MIR21
8 inferior myocardial infarction 12.7
9 anterolateral myocardial infarction 12.7
10 myocardial infarction 2 12.6
11 posterior myocardial infarction 12.6
12 anteroseptal myocardial infarction 12.6
13 silent myocardial infarction 12.6
14 septal myocardial infarction 12.6
15 subendocardial myocardial infarction 12.6
16 acute anterolateral myocardial infarction 12.6
17 acute inferolateral myocardial infarction 12.6
18 lateral myocardial infarction 12.6
19 apical myocardial infarction 12.6
20 posterolateral myocardial infarction 12.6
21 strictly posterior acute myocardial infarction 12.6
22 posteroinferior myocardial infarction 12.6
23 subendocardial infarction acute myocardial infarction 12.4
24 inferolateral myocardial infarct 12.4
25 coronary artery disease, autosomal dominant, 1 12.4
26 coronary thrombosis 12.0
27 ventricular fibrillation, paroxysmal familial, 1 11.9
28 cardiac rupture 11.8
29 atherosclerosis susceptibility 11.8
30 kawasaki disease 11.7
31 hyperlipidemia, familial combined, 3 11.7
32 thrombophilia due to thrombomodulin defect 11.7
33 werner syndrome 11.7
34 conn's syndrome 11.7
35 cardiogenic shock 11.4
36 acute inferoposterior infarction 11.4
37 hyperaldosteronism, familial, type ii 11.3
38 coronary artery disease, autosomal dominant 2 11.3
39 thrombocythemia 3 11.3
40 morbid obesity and spermatogenic failure 11.3
41 chronic mountain sickness 11.3
42 arterial calcification of infancy 11.3
43 aldosterone-producing adenoma 11.3
44 ischemia 11.3
45 intermediate coronary syndrome 11.3
46 angina pectoris 11.3
47 congestive heart failure 11.3
48 progressive familial heart block, type ia 11.2
49 lipoprotein quantitative trait locus 11.2
50 hyperlipoproteinemia, type iii 11.2

Graphical network of the top 20 diseases related to Myocardial Infarction:



Diseases related to Myocardial Infarction

Symptoms & Phenotypes for Myocardial Infarction

Clinical features from OMIM:

608446

UMLS symptoms related to Myocardial Infarction:


edema, chest pain, angina pectoris

Drugs & Therapeutics for Myocardial Infarction

PubMed Health treatment related to Myocardial Infarction: 62

Early treatment for a heart attack can prevent or limit damage to the heart muscle . Acting fast, at the first symptoms of a heart attack, can save your life. Medical personnel can begin diagnosis and treatment even before you get to the hospital. Certain treatments usually are started right away if a heart attack is suspected, even before the diagnosis is confirmed. These include: Oxygen therapy Aspirin to thin your blood and prevent further blood clotting Nitroglycerin to reduce your heart 's workload and improve blood flow through the coronary arteries Treatment for chest pain Once the diagnosis of a heart attack is confirmed or strongly suspected, doctors start treatments to try to promptly restore blood flow to the heart. The two main treatments are "clot-busting" medicines and percutaneous coronary intervention (PCI), sometimes referred to as coronary angioplasty , a procedure used to open blocked coronary arteries .

Drugs for Myocardial Infarction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 909)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimetazidine Approved, Investigational Phase 4 5011-34-7
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
4
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
5
Glyburide Approved Phase 4 10238-21-8 3488
6
Methadone Approved Phase 4 76-99-3 4095
7
Eplerenone Approved Phase 4 107724-20-9 150310 443872
8
Glucagon Approved Phase 4 16941-32-5
9
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
10
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
11
Abciximab Approved Phase 4 143653-53-6
12
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Lenograstim Approved, Investigational Phase 4 135968-09-1
16
Pantoprazole Approved Phase 4 102625-70-7 4679
17
Warfarin Approved Phase 4 81-81-2 6691 54678486
18
Reteplase Approved, Investigational Phase 4 133652-38-7 65820
19
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
20
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
21
Ticlopidine Approved Phase 4 55142-85-3 5472
22
Fondaparinux Approved, Investigational Phase 4 104993-28-4
23
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
24
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
25
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
26
Acetaminophen Approved Phase 4 103-90-2 1983
27
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
28
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
29
Doxazosin Approved Phase 4 74191-85-8 3157
30
Gliclazide Approved Phase 4 21187-98-4 3475
31
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
32
Streptokinase Approved, Investigational Phase 4 9002-01-1
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Hydroxychloroquine Approved Phase 4 118-42-3 3652
35
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
36
Anthralin Approved Phase 4 1143-38-0
37
Edaravone Approved, Investigational Phase 4 89-25-8 70335
38
Famotidine Approved Phase 4 76824-35-6 3325
39
Histamine Approved, Investigational Phase 4 51-45-6 774
40
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
41
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
42
Fenofibrate Approved Phase 4 49562-28-9 3339
43 Apricot Approved Phase 4
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
46
Aminophylline Approved Phase 4 317-34-0 9433
47
Ibuprofen Approved Phase 4 15687-27-1 3672
48
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
49
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
50
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594

Interventional clinical trials:

(show top 50) (show all 5426)
# Name Status NCT ID Phase Drugs
1 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
2 Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL) Unknown status NCT02170103 Phase 4 Microbubbles
3 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
4 Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size Unknown status NCT01936285 Phase 4 Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;Placebo
5 Randomized Controlled Study of a Rapid "Rule Out" Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes Unknown status NCT00933400 Phase 4
6 Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction. Unknown status NCT01080638 Phase 4 glycoprotein IIb/IIIa inhibitor (abciximab)
7 Effects of Intensive Statin Therapy on Left Ventricular Function for Patients With the First Acute Anterior Myocardial Infarction After Directly to Percutaneous Coronary Intervention. Unknown status NCT01936103 Phase 4 standard group;intensive group
8 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
9 Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor Unknown status NCT02422888 Phase 4 Ticagrelor;Prasugrel
10 Treating Acute MI Patients With Aggrastat on Their Way to Hospital Unknown status NCT00300833 Phase 4 Tirofiban
11 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
12 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
13 Intracoronary Cocktail Injection Combined With Thrombus Aspiration in ST-elevation Myocardial Infarction Patients Treated With Primary Angioplasty Unknown status NCT02592694 Phase 4 cocktail
14 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
15 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
16 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl Unknown status NCT00688922 Phase 4 Pravastatin
17 High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial. Unknown status NCT02224534 Phase 4 Ticagrelor;Clopidogrel
18 Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI Unknown status NCT00288210 Phase 4
19 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
20 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
21 A Randomized Trial to Compare Four Different Intracoronary Modalities to Reduce Thrombus Burden and Improve Microcirculatory Function in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the COCTAIL II Study Unknown status NCT01499407 Phase 4 Abciximab
22 Immediate Versus Delayed Stenting in Patients With ST-Elevation Myocardial Infarction Undergoing Mechanical Intervention Unknown status NCT01462188 Phase 4
23 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
24 The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction Unknown status NCT01372930 Phase 4 Etanercept;saline
25 Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
26 Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention Unknown status NCT02123004 Phase 4 Ticagrelor;Clopidogrel
27 Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents Unknown status NCT01781715 Phase 4
28 Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine Unknown status NCT02281305 Phase 4 Colchicine
29 Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary PCI Unknown status NCT03045562 Phase 4 Normal saline;Salvianolate injection
30 Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention Unknown status NCT01968577 Phase 4 Rosuvastatin
31 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
32 Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) Unknown status NCT02428374 Phase 4 Rosuvastatin plus clopidogrel;Rosuvastatin plus ticagrelor;Simvastatin plus clopidogrel;Simvastatin plus ticagrelor
33 Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI Unknown status NCT00976092 Phase 4 Prasugrel;Bivalirudin;Clopidogrel;Heparin
34 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
35 The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial Unknown status NCT02835534 Phase 4 rhTNK-tPA;alteplase
36 Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial Unknown status NCT00229515 Phase 4
37 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
38 Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study. Unknown status NCT01914055 Phase 4
39 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
40 Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography Unknown status NCT01875835 Phase 4
41 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study. Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
42 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
43 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
44 Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter Unknown status NCT01383785 Phase 4
45 Effect of Vitamin C Infusion on Coronary Reperfusion Indexes Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
46 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
47 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
48 MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial Unknown status NCT01124942 Phase 4
49 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
50 Polish-Italian-Hungarian RAndomized ThrombEctomy Trial. PIHRATE Trial. Unknown status NCT00377650 Phase 4

Search NIH Clinical Center for Myocardial Infarction

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acebutolol
Acebutolol Hydrochloride
alteplase
anisindione
Anistreplase
Atenolol
Bisoprolol
Bisoprolol Fumarate
carvedilol
carvedilol phosphate
Dalteparin
Dalteparin Sodium
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
DITIAZ
Enoxaparin
eptifibatide
esmolol
Esmolol hydrochloride
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Labetalol
Labetalol hydrochloride
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
Lisinopril
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Nadolol
Nitroglycerin
Penbutolol
Penbutolol Sulfate
Pindolol
Propranolol
Propranolol Hydrochloride
Reteplase
Streptokinase
Sulfinpyrazone
Tenecteplase
Timolol
Timolol Hemihydrate
Timolol Maleate
tirofiban
TIROFIBAN HYDROCHLORIDE
Urokinase
Verapamil
Verapamil hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myocardial Infarction cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myocardial Infarction:
ADRCs, adipose-derived regenerative cells for cardiovascular disease
AMI MultiStem, bone marrow-derived cells for acute myocardial infarction
AMR-001, bone marrow-derived CD34+ cells for myocardial infarction
Autologous bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow or peripheral blood-derived stem cells for treatment of myocardial ischemia
Bone marrow-derived adult mononuclear cells for heart diseases
Bone marrow-derived CD133+ vs. mononuclear cells for treatment of myocardial infarction
Bone marrow-derived mesenchymal stem cells for treatment of myocardial ischemia
Bone marrow-derived mononuclear cells for acute myocardial infarction
Bone marrow-derived mononuclear cells for chronic myocardial infarction
Bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow-derived mononuclear cells for treatment of myocardial infarction
Bone marrow-derived progenitor cells for myocardial infarction
Bone marrow-derived stem cells for treatment of ischemic cardiomyopathy
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
Cardiosphere-derived cells for the treatment of myocardial infarction
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
Combination therapy of mononuclear cells with laser for coronary disease
Early endothelial progenitor cells for acute myocardial infarction
Embryonic stem cell-derived cardiomyocyte transplantation for myocardial infarction
Embryonic stem cell-derived cardiomyocytes for treatment of myocardial infarction
Enriched bone marrow-derived progenitor cells for heart diseases
Hearticellgram-AMI, mesenchymal stem cells for acute myocardial infarction
Hydrogels with cardiomyocytes for myocardial repair
Induced pluripotent stem cells for treatment of myocardial infarction
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesenchymal precursor cells for cardiovascular diseases
Mesendo, stem cell combination for treatment of cardiovascular diseases
MyoCell, muscle stem cells for severe heart damage
Prochymal, mesenchymal stem cells for treatment of acute myocardial infarction
Sca-1-positive cardiac progenitor cells for treatment of myocardial infarction
Stem cell therapy for treatment of acute myocardial infarction
StempeucelAMI, mesenchymal stem cells for acute myocardial infarction
Umbilical cord blood-derived CD133 positive cells for treatment of myocardial infarction
Embryonic/Adult Cultured Cells Related to Myocardial Infarction:
Adipose-derived stem and regenerative cells PMIDs: 22281257 21082397
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285 22052917 22004910 23111647
Bone marrow-derived autologous CD34+cells (AMR-001) PMIDs: 21167340
Bone marrow-derived mononuclear cells PMIDs: 19002124
Bone marrow-derived mononuclear cells
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mononuclear cells PMIDs: 20524773 20445812 19699857 22137069
Bone marrow-derived CD133+ hematopoietic stem cells
Bone marrow-derived mononuclear cells (family) PMIDs: 16382259 16889856 22192151 21414223 22940024 21392602
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells PMIDs: 22834565
Bone marrow-derived mesenchymal stem cells PMIDs: 16382259 16889856
Bone marrow-derived mononuclear cells PMIDs: 22834565
Bone marrow-derived mononuclear cells
Bone marrow-derived progenitor cells PMIDs: 20448133 18293890 16159812
Porcine bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602 19958962
Bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Cardiosphere-derived cells PMIDs: 22336189 17283259
Bone marrow-derived CD133+ cells PMIDs: 17320570
Peripheral blood-derived endothelial progenitor cells PMIDs: 22239631 21362705
eNOS-transfected endothelial progenitor cells PMIDs: 22239631 21362705
Cardiomyocyte-like cells PMIDs: 17980256 21783246
Cardiomyocyte-like cells PMIDs: 22040108
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Neonatal rat ventricular cardiomyocytes PMIDs: 21783246
DR4 induced pluripotent stem cells PMIDs: 23568891
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Bone marrow-derived mononuclear cells PMIDs: 21323410 20631864
Bone marrow-derived mesenchymal stem cells PMIDs: 21323410 20631864
Skeletal myoblasts (MyoCell) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mesenchymal stem cells PMIDs: 19958962
Cardiac progenitor cells (Sca1+) PMIDs: 21980409
Bone marrow-derived CD34+/CXCR4+ cells
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord blood-derived CD133+ cells PMIDs: 16195418

Cochrane evidence based reviews: myocardial infarction

Genetic Tests for Myocardial Infarction

Genetic tests related to Myocardial Infarction:

# Genetic test Affiliating Genes
1 Myocardial Infarction 1 29 ESR1 F13A1 F7 GCLC GCLM ITGB3 LGALS2 LRP8 LTA MIAT OLR1 PSMA6 TNFSF4
2 Myocardial Infarction 29

Anatomical Context for Myocardial Infarction

MalaCards organs/tissues related to Myocardial Infarction:

40
Heart, Bone, Endothelial, Testes, Kidney, Bone Marrow, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myocardial Infarction:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Heart Myocardium Cardiomyocytes Affected by disease

Publications for Myocardial Infarction

Articles related to Myocardial Infarction:

(show top 50) (show all 35790)
# Title Authors PMID Year
1
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. 61 56 6
17847002 2007
2
Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. 61 6
17066261 2006
3
Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. 6 54
15129282 2004
4
Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. 54 6
12646194 2003
5
Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. 54 6
10587578 2000
6
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. 54 6
8644984 1996
7
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 6 54
8541160 1995
8
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. 54 6
7854377 1995
9
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 54 6
8170965 1994
10
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. 6 54
8131299 1993
11
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. 54 6
8131300 1993
12
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. 54 6
1328889 1992
13
Plasma microRNA 499 as a biomarker of acute myocardial infarction. 61 46
20395621 2010
14
MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. 46 61
20029200 2010
15
Replication studies for the association of PSMA6 polymorphism with coronary artery disease in East Asian populations. 6
19282875 2009
16
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 6
19221299 2009
17
Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. 6
17393027 2007
18
Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. 6
17264806 2007
19
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. 6
16845397 2006
20
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 6
15635071 2005
21
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 6
15531537 2004
22
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 6
15534175 2004
23
ACE1 polymorphism and progression of SARS. 6
15381116 2004
24
A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. 6
15266304 2004
25
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 6
15277638 2004
26
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 6
15110771 2004
27
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. 56
14732905 2004
28
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 6
14872014 2004
29
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
30
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 6
14657821 2003
31
Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. 6
14684693 2003
32
Association between estrogen receptor alpha gene variation and cardiovascular disease. 6
14600184 2003
33
Polymorphism in glutamate-cysteine ligase modifier subunit gene is associated with impairment of nitric oxide-mediated coronary vasomotor function. 6
12975258 2003
34
Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. 6
12810610 2003
35
Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. 6
12456499 2003
36
Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. 6
12774036 2003
37
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6
12746914 2003
38
Phenotype modulators in myophosphorylase deficiency. 6
12666117 2003
39
Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. 6
12598062 2003
40
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. 6
12426569 2002
41
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 6
12220450 2002
42
Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. 6
12081989 2002
43
The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g. 6
12072871 2002
44
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 6
11956052 2002
45
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. 6
11919305 2002
46
Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. 6
11894143 2002
47
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 6
11687636 2001
48
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. 6
11723016 2001
49
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. 6
10984565 2000
50
The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. 6
10910914 2000